ArticleJournal of Korean medical science2026
Comparison of Vaccine Adverse Events Between Zoster Vaccine Live and Recombinant Zoster Vaccine: A Prospective Multicenter Survey.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe burden of herpes zoster has been mitigated through the introduction of two types of vaccines, including zoster vaccine live (ZVL) and recombinant zoster vaccine (RZV). We aimed to compare the occurrence of adverse events within 90 days of vaccination.
methodsWe prospectively enrolled participants who received ZVL or RZV between October 2022 and November 2024 at five tertiary hospitals and nine primary care clinics in South Korea. Data on solicited and unsolicited adverse events were collected using questionnaires at 1, 3, 7, 28, and 90 days after vaccination. Demographic and clinical data including vaccination history, previous episodes of herpes zoster, underlying diseases, and immune status were also collected. Multivariable logistic regression analysis was conducted to assess the risk of solicited adverse events according to clinical variables.
resultsIn total, 1,527 participants were enrolled, with 487 receiving ZVL, 632 receiving the first RZV dose, and 408 receiving the second RZV dose. In multivariable logistic regression analysis after adjusting clinical variables, the adjusted odds ratios (ORs) for the risk of solicited adverse events at day 1 were significantly lower in 11 categories for the ZVL group compared to the first-dose RZV group. However, for the second-dose RZV group, the adjusted ORs were significantly higher in 9 categories when compared to the first-dose RZV group. No life-threatening vaccine-related events occurred in the unsolicited adverse event reports between days 8 and 90.
conclusionAfter adjusting for clinical variables, the risks of many solicited adverse events were highest in the second-dose RZV group, followed by the first-dose RZV group, and were lowest in the ZVL group. However, the differences in risk diminished from day 1 to day 7. No fatal events occurred in either group. Clinicians should be aware of early reactogenicity of RZV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.